関連する実験動画
Updated: Jun 29, 2025

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.8K
ナトリウム・グルコース・コトランスポーター-2 阻害剤と主要な不良心血管結果: SMART-C 共同メタ解析
Siddharth M Patel1,2, Yu Mi Kang1,3, KyungAh Im1,2
1TIMI Study Group (S.M.P., Y.M.K., K.I., M.S.S., S.D.W.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Circulation
|April 7, 2024
まとめ
ナトリウム・グルコース・コトランスポーター2阻害剤 (SGLT2i) は,様々な患者グループにおいて,重大な心血管疾患 (MACE) を有意に減少させる. この利点は主に心血管疾患による死亡,特に心不全や突然の心臓死による死亡の減少によるものです.
科学分野:
- 心臓病科
- 腎臓科
- 代謝疾患の研究
背景:
- ナトリウム・グルコース・コトランスポーター2阻害剤 (SGLT2i) は,心不全および腎臓疾患のアウトカムを改善することが知られている.
- しかし,様々な患者集団における主要な心血管不良事件 (MACE) に対する影響については,さらなる明確化が必要である.
研究 の 目的:
- SGLT2阻害剤がMACEおよびその成分に及ぼす影響を評価する試験レベルの共同メタ分析を実施する.
- 動脈硬化性心血管疾患リスク,心不全,慢性腎臓疾患を含む異なる患者集団でこれらの効果を調べる.
主な方法:
- 78, 607人の患者を対象とした,プラセボ対照のSGLT2阻害剤試験のメタ分析.
- 評価されたアウトカムには,MACE,その個々の成分,あらゆる原因による死亡率,および死亡サブタイプが含まれていた.
- 既定の心血管疾患,糖尿病,腎臓疾患の段階,アルブミヌリアに基づいてサブグループ分析を行った.
主要な成果:
- SGLT2阻害剤は,すべての患者集団およびサブグループで一貫してMACEを9% (HR,0. 91) 減少させた.
- この減少の主な要因は,心血管疾患による死亡 (HR,0. 86) の減少であり,特に心不全による死亡と突然の心疾患による死亡でした.
- 心筋梗塞 (HR,0. 95) や脳卒中 (HR,0. 99) に関する有意な効果は観察されなかった.
結論:
- SGLT2阻害剤は,初期臨床特性に関係なく,幅広い患者でMACEのリスクを効果的に軽減します.
- 心血管疾患の効果は主に心血管疾患による死亡,特に心不全や突然の心疾患による死亡の減少と関連しています.
- これらの発見は,心血管,腎臓,代謝疾患の管理においてSGLT2阻害剤の使用を支持する.
関連する概念動画
Oral Hypoglycemic Agents: Biguanides and Glitazones
195
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
195
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Dipeptidyl Peptidase 4 Inhibitors
182
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182
Secondary Active Transport
119.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
119.6K
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K

